✦ LIBER ✦

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

✍ Scribed by A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fatima Dias Gaui; D. Otero Reyes; J. Jassem; P. Button; R. Bell

Book ID: 119598019
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 69 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)70525-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

194 A Phase II Study of Trastuzumab Plus

194 A Phase II Study of Trastuzumab Plus Capecitabine with or Without Pertuzumab for HER2-positive Metastatic Breast Cancer as Second-line Treatment (PHEREXA)

✍ A. Urruticoechea; P. Canney; R. Separovic; T. Bachelot; J. Efran; J.L. Canon; P. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

2132 POSTER Economic impact of adding ca

2132 POSTER Economic impact of adding capecitabine (X) to docetaxel (T) and trastuzumab (H) as first-line therapy for HER2-positive advanced or metastatic breast cancer

✍ A. Bonetti; A. Santoro; P. Ducournau; A. Cirrincione; G. Giuliani; R. Bell 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A phase I/II trial of non-pegylated lipo

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

✍ D. Amadori; C. Milandri; G. Comella; S. Saracchini; S. Salvagni; C. Barone; R. B 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 226 KB

672 Randomised phase II trial (M77001) o

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

✍ J.-M. Extra; F. Cognetti; S. Chan; D. Maraninchi; R. Snyder; a. Lluch; M. Tubian 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Trastuzumab with either docetaxel or vin

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

✍ Stefania Redana; Michela Donadio; Franco Nolè; Maria Elena Jacomuzzi; Alessandra 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 309 KB

An exploratory study of sunitinib in com

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

✍ Fatima Cardoso; Jean-Luc Canon; Dino Amadori; Daniela Aldrighetti; Jean-Pascal M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 383 KB